Join us for a networking event focussing on oncology start-ups looking to gain insights, share experiences and connect with key players in the Medicon Valley oncology ecosystem.
This event will bring together innovative start-ups, and industry experts to explore the dos and don’ts of building a successful oncology company. Through insightful presentations, real-life case studies and panel discussions, attendees will gain a deeper understanding of the Medicon Valley oncology eco system.
Why attend?
- Learn from experienced oncology start-ups as they share key lessons from their journeys
- Gain insights into the oncology ecosystem and global market trends
- Get valuable feedback from a panel of serial entrepreneurs, and industry leaders
- Expand your network and connect with potential collaborators and mentors
Citeline has conducted an analysis on the oncology ecosystem in Sweden and Denmark and will present their key findings at the event. Don’t miss this opportunity to gain fresh perspectives and strengthen your network in the dynamic world of oncology innovation.
Date: 8th May 2025
Time: 14:00-18:30
Venue: Medicon Valley Alliance, HUB 2, Arne Jacobsens Allé 15, 2300 Copenhagen
Program:
| 14.00 | Registration and networking |
| 14:30 | Welcome Anette Steenberg, CEO, Medicon Valley Alliance |
| 14:40 | Citeline analysis: Key Trends in Global vs Swedish and Danish Oncology Markets Millie Gray, Commercial Intelligence Product Analyst, Citeline Ellie Davenport, Solution Consultant, Citeline |
| 15:10 | ONCOLOGY START-UP PRESENTATIONS
|
| 16:10 | Coffee Break |
| 16:40 | IP due diligence Janni Wandahl Pedersen, HØIBERG European Patent Attorneys |
| 16:50 | Panel Feed-back – Advice and perspective Moderated by Umar Adegoke, Associate, Venture Creation, BioInnovation Institute |
In the panel:
|
|
| 17:20 | Networking session with drinks and light catering |
| 18:30 | End of meeting |
Speakers
 |
Mette Trauelsen, is CEO and co-founder of SOLID Therapeutics – a preclinical-stage oncology company spun out in 2022 from the University of Copenhagen’s NNF Center for Basic Metabolic Research. The company is developing first-in-class small molecule inhibitors targeting a novel, tumor-promoting GPCR for the treatment of a variety of solid tumors. |
 |
Morten Albrechtsen is CEO of FluoGuide. He is an MD and BBA (‘HD’ in marketing, CBS). Morten is a seasoned entrepreneur with a strong medical, commercial and financial background. The expertise is gained within a broad range of therapeutic areas and with both drugs and devices. |
 |
Christoffer F. Nielsen is VP Operations, General Manager the co-founder of Adcendo ,which was spun out from The Finsen Laboratory at Rigshospitalet and BRIC/UCPH in 2017. Initially founding the company on a novel concept derived from work conducted at the academic lab, Adcendo is today a clinical-stage biotech with approximately 50 employees and a growing pipeline of oncology drugs of the antibody-drug conjugate (ADC) class. Christoffer has held several different roles in Adcendo, initially as a scientist, but today focusing solely on operational matters as the General Manager. |
 |
Emma Leire is a Translational Scientist with over 10 years of experience in immunotherapy biotech. She leads the Translational and Clinical biomarker strategy at Asgard Therapeutics, developing novel cancer immunotherapies. Previously, she was Director of Translational Biomarkers at Achilles Therapeutics and Biology Project Lead at Centauri Therapeutics. She holds a PhD in Nanomedicine and Pharmaceutical Innovation from the University of Nottingham. |
 |
Magnus Corfitzen is CEO of Ascelia Pharma AB (publ). Magnus has extensive experience from investing, building and growing Life Science companies in various roles including operational activities or investment responsibilities for public and private biotech and medtech companies. Magnus also has board experience from 10+ Life Science companies. |
| Moderator | |
 |
Umar Adegoke is an associate in BII’s Venture Creation team. Previously, he worked with early-stage innovation at Illumina Accelerator (UK) and venture capital at Trill Impact Ventures (Sweden). He also has experience in health tech startups and briefly practiced clinical medicine in Nigeria. Umar holds a medical degree from the University of Lagos and a master’s in bioentrepreneurship from Karolinska Institute. |
| Panellists | |
 |
Anki Malmborg Hager has extensive experience from starting life science companies originating from Lund university research. She is currently CEO of Lead Biologics International AB and has previously served as CEO of SenzaGen, PainDrainer AB, Cantargia AB, XImmune AB and Diaprost AB. Before that, she was Investment Director at LU Bioscience AB and VP Business Development at Alligator Bioscience AB. Education: PhD in Immunotechnology, MSc in Chemical Engineering, Pharma MBA. Other appointments: Board director at SenzaGen AB, NanoEcho AB, and Pharma Holding AS. |
 |
Thomas Areschoug has extensive experience of business development, investment promotion and biomedical R&D in the Life Science sector. Thomas has held leading positions at management team level as CBO in Xintela AB and Targinta AB, and has previously led the investment promotion work in Life Sciences at Business Sweden. He has also engaged in board work in biotech, and has worked as consultant and scientific advisor. Thomas holds a PhD in Medical Microbiology from Lund University. |
 |
Malin Carlsson, MD, Ph.D, has more than 15 years of experience in early and clinical-stage drug development and translational medicine and an academic background in clinical immunology. Malin curentlu serves as the General Manager for Symphogen, a Servier company in Ballerup Denmark, and has previously held various leadership positions Takeda, AstraZeneca, Ferring and Alligator Bioscience. Malin has in-depth experience in drug discovery development, mainly antibody therapeutics, in the therapeutic areas of inflammation and oncology. |
 |
Claus Møller is the Founder and CEO of AFYX Therapeutics A/S. Previously he was Co-Founder and CEO of Y-mAbs, Inc and secured its IPO in 2018 and he was also Co-Founder of Genmab back in 1999. |
 |
Hans Schambye is an experienced biotech entrepreneur and executive with solid background in corporate strategy, financing and management, drug discovery and development. Based on a background as a Medical Doctor and scientist (PhD in Molecular Pharmacology) the core expertise is biological understanding of disease combined with extensive experience with drug discovery and development, business development, and portfolio management. |
Deadline for registration is 6th of May
The MVA Oncology network
Joining the MVA Oncology Network is free of charge but is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate the relevance in joining the network. For more information please contact Katrine Brems Olsen at kbo@mva.org
| Organized by | |
 |
|
| Sponsor | Analysis sponsor |
 |
 |